This Month's Highlights

UP FRONT MATTERS

Editorials
873 Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy
Chee Kay Cheung and Jonathan Barratt
  • See related article by Zachova et al. (pp. 908–917).

875 A View on Cathepsin C as a Target for Therapy in AAV
Renate Kain and Maja C. Nackenhorst
  • See related article by Jerke et al. (pp. 936–947).

878 Clonal Hematopoiesis and CKD Progression
Abhishek Niroula and Roger Belizaire
  • See related article by Vlasschaert et al. (pp. 985–995).

Perspective
880 Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Fahad Saeed, Alvin H. Moss, Paul R. Duberstein, and Kevin A. Fiscella

RESEARCH LETTER
883 SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients

BASIC RESEARCH
889 DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants
Justin Chun, Cristian V. Riella, Hyunjae Chung, Shrijal S. Shah, Minxian Wang, Jose M. Magraner, Guilherme T. Ribas, Hennrique T. Ribas, Jia-Yue Zhang, Seth L. Alper, David J. Friedman, and Martin R. Pollak

908 Galactose-Deficient IgA1 B Cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors
Katerina Zachova, Jana Jemelkova, Petr Koszytu, Yukako Ohyama, Kazuo Takahashi, Josef Zadrazil, Jiri Orsag, Karel Matousovic, Dana Galuszikova, Nadezda Petjeova, Jiri Mestecky, and Milan Raska
  • See related editorial by Cheung and Barratt (pp. 873–875).

918 Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy
Xinfang Xie, Jingyi Li, Pan Liu, Manliu Wang, Li Gao, Feng Wan, Jicheng Lv, Hong Zhang, and Jing Jin

936 Targeting Cathepsin C in PR3-ANCA Vasculitis
Uwe Jerke, Claudia Eulenberg-Gustavus, Anthony Rousselle, Paul Nicklin, Stefan Kreideweiss, Marc A. Grundl, Peter Eickholz, Katrin Nickles, Adrian Schreiber, Brice Korkmaz, and Ralph Kettritz
  • See related editorial by Kain and Nackenhorst (pp. 875–878).

949 Serum Protein Exposure Activates a Core Regulatory Program Driving Human Proximal Tubule Injury

Red star ★ indicates articles that are features in This Month’s Highlights.
Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor

**CLINICAL EPIDEMIOLOGY**

Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease

See related editorial by Niroula and Belizaire (pp. 878–879).

Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D
Teresa K. Chen, Steven G. Coca, Michelle M. Estrella, Lawrence J. Appel, Josef Coresh, Heather Thiessen Philbrook, Wassim Obeid, Linda F. Fried, Hiddo J.L. Heerspink, Joachim H. Ix, Michael G. Shlipak, Paul L. Kimmel, Chirag R. Parikh, and Morgan E. Grams, on behalf of the CKD Biomarkers Consortium (BioCon)

**CLINICAL RESEARCH**

Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials
Chelsea Xu, Edward R. Smith, Mark K. Tiong, Irene Ruderman, and Nigel D. Toussaint

Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1

**LETTERS TO THE EDITOR**

More Research is Still Needed To Support The Real-world Generalizability of The Benefits of Lifestyle Interventions for CKD
Liuyan Huang and Fan Zhang

Authors’ Reply: More Research is Still Needed to Support the Real-World Generalizability of the Benefits of Lifestyle Interventions for Chronic Kidney Disease
Kassia S. Beetham, Jeff S. Coombes, and Erin J. Howden
• See related letter to the editor, “Effect of a 3-Year Lifestyle Intervention in Patients with Chronic Kidney Disease: A Randomized Clinical Trial,” in Vol. 33, Iss. 2, on pages 431–441.

The Subcellular Localization of RRAGD
Tiantian Ma, Lei Zhang, and Limeng Chen
• See related reply, “Authors’ Reply: The Subcellular Localization of RRAGD,” on pages 1048–1049, and original article, “mTOR-Activating Mutations in RRAGD are Causative for Kidney Tubulopathy and Cardiomyopathy,” in Vol. 32, Iss. 11, on pages 2885–2899.

Authors’ Reply: The Subcellular Localization of RRAGD
Karl P. Schlingmann, François Jourret, Nine V.A.M. Knoers, and Jeroen H.F. de Baaij
See related letter to the editor, “The Subcellular Localization of RRAGD,” on pages 1046–1048, and original article, “mTOR-Activating Mutations in RRAGD are Causative for Kidney Tubulopathy and Cardiomyopathy,” in Vol. 32, Iss. 11, on pages 2885–2899.

Correction: Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome